A Pilot Study Of Pharmacotherapy (Naltrexone) For Hazardous Drinking Among Women Infected With HIV

Methods: The NIAAA-sponsored pilot study was a double-blind, randomized controlled trial. Women with HIV who met criteria for past-year hazardous drinking were recruited from HIV clinical settings in Jacksonville (FL) and the Women’s Interagency HIV Study (WIHS) in Chicago (IL) and Washington DC. Participants were randomized 2:1 to oral naltrexone (50mg) or placebo for 4 months; outcomes were assessed 2, 4 and 7 months after enrollment.